Trials / Completed
CompletedNCT01455194
Effect of High Dose Ciclesonide on Asthma Control
Control of Moderate or Severe Asthma With 160, 320 and 640 mcg Ciclesonide/Day. A One-year Randomised, Double-blind, Multicenter Trial.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 520 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 12 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the trial is to investigate asthma control with 160 to 640 mcg ciclesonide/day. Asthma control will be assessed by the Asthma Control Questionnaire (ACQ).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ciclesonide | During the treatment period subjects will inhale two puffs of either 40, 80 or 160 μg ciclesonide in the morning and the evening (corresponding to a total daily dose of 160, 320 or 640 μg) |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2014-08-01
- Completion
- 2014-08-01
- First posted
- 2011-10-19
- Last updated
- 2017-02-10
- Results posted
- 2016-10-25
Locations
30 sites across 5 countries: Argentina, Brazil, Germany, Israel, Russia
Source: ClinicalTrials.gov record NCT01455194. Inclusion in this directory is not an endorsement.